CEL-SCI Scientist Presents at the World Vaccine Congress
April 12 2017 - 08:30AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) today
announced that Dr. Daniel Zimmerman, its Senior Vice President of
Research, Cellular Immunology, is presenting at the 17th Annual
World Vaccine Congress held in Washington D.C. on April 12, 2017.
The conference runs from April 10-12, 2017. The title of his
presentation is “Unmet need for therapeutic vaccines for autoimmune
conditions with emphasis on arthritis – and a look into the
future.”
At the conference, Dr. Zimmerman is presenting data supporting a
potentially novel approach to fighting the inflammation in the
joints caused by rheumatoid arthritis. He introduced animal data
that demonstrates that using CEL-SCI’s LEAPS CEL-4000 Rheumatoid
Arthritis treatment vaccine downregulates pro-inflammatory T-cell
responses and upregulates anti-inflammatory T-cell responses. This
finding was confirmed by an examination of cytokines in the serum
of the animals and by earlier data on CEL-4000 and CEL-2000 in the
two animal models examined. Information on other autoimmune
conditions showing either a Th1 or Th17 signature cytokine profile
was cited and supportive as well.
Dr. Zimmerman said, “I believe based on the above findings and
observations of others that the future of this novel approach using
LEAPS therapeutic vaccines could be expanded to other autoimmune
conditions with similar Th1 and Th17 signature cytokine phenotypes
including multiple sclerosis, autoimmune uveitis, and type I
diabetes.”
About the World Vaccine Congress
The World Vaccine Congress is now well-established as the must
attend global vaccine event each year, where leaders of the
industry come to discuss science and do business. Now in its 17th
year, the event in 2017 will bring over 700 senior vaccine
executives to learn, meet and form partnerships. - See more at:
http://www.terrapinn.com/conference/world-vaccine-congress-washington/our-Story.stm#sthash.Cjiak553.dpuf
About LEAPS
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a
CEL-SCI patented platform technology designed to stimulate
antigen-specific immune responses in T-cells using synthetic
peptides. LEAPS constructs physically link the antigenic peptide
with a T-cell binding ligand and are delivered directly to the
recipient immune system by injection or mucosal absorption,
potentially enhancing T-cell responses to a particular antigen.
About CEL-SCI
CEL-SCI's work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. The
Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K and 10-K/A for
the year ended September 30, 2016. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170412005106/en/
CEL-SCI CorporationGavin de Windt,
703-506-9460www.cel-sci.com
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2023 to Mar 2024